Comparing Acutus Medical (NASDAQ:AFIB) and Nemaura Medical (NASDAQ:NMRD)

Risk & Volatility

Acutus Medical has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.

Insider and Institutional Ownership

56.9% of Acutus Medical shares are owned by institutional investors. Comparatively, 4.4% of Nemaura Medical shares are owned by institutional investors. 5.2% of Acutus Medical shares are owned by insiders. Comparatively, 40.4% of Nemaura Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Acutus Medical and Nemaura Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acutus Medical	$7.16 million	0.23	-$81.66 million	N/A	N/A
Nemaura Medical	$80,000.00	0.00	-$14.14 million	($0.39)	N/A

Nemaura Medical has lower revenue, but higher earnings than Acutus Medical.

Profitability

This table compares Acutus Medical and Nemaura Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acutus Medical	-272.74%	-311.64%	-11.57%
Nemaura Medical	N/A	N/A	N/A

Summary

Nemaura Medical beats Acutus Medical on 6 of the 8 factors compared between the two stocks.

About Acutus Medical

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.